## Type I Endometrial Carcinoma: Immunophenotype as Discriminator ### Molecular & Immunohistochemical Profile **Key Point:** Type I endometrial carcinomas retain estrogen receptor (ER) and progesterone receptor (PR) expression and typically show wild-type or low p53 expression; Type II carcinomas lose ER/PR and show p53 overexpression due to TP53 mutations. ### Immunohistochemical Distinction | Marker | Type I (Endometrioid) | Type II (Serous/Clear Cell) | | --- | --- | --- | | **ER/PR** | Positive (retained) | Negative (lost) | | **p53** | Wild-type or low (normal pattern) | Overexpressed (abnormal accumulation) | | **PTEN** | Loss common | Usually retained | | **Mismatch repair proteins** | Deficient in ~20–30% | Usually intact | | **Molecular basis** | PTEN, KRAS, PIK3CA mutations | TP53 mutations | ### Clinical Pearl **Clinical Pearl:** In a 52-year-old obese woman with irregular bleeding and grade 1 endometrioid carcinoma, the combination of **ER/PR positivity + p53 negativity** is the immunophenotypic hallmark of Type I disease. This pattern reflects the estrogen-driven, PTEN/KRAS-mutant molecular background and predicts a favorable prognosis and responsiveness to hormone therapy if needed. ### High-Yield Mnemonic **Mnemonic:** **ER/PR+ p53−** = **Type I** (endometrioid, estrogen-driven, early-stage); **ER/PR− p53+** = **Type II** (serous, TP53-mutant, aggressive). ### Why This Matters Immunophenotyping is faster and more reproducible than molecular sequencing in routine practice. The presence of ER/PR and absence of p53 overexpression in a low-grade tumor strongly support Type I biology and predict better outcomes with surgery alone, whereas ER/PR loss and p53 overexpression indicate Type II biology requiring adjuvant chemotherapy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.